oNKord®

DRUG2 trials

Sponsors

Glycostem Therapeutics BV

Conditions

AMLAcute Myeloid Leukemia

Phase 1

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Glycostem Therapeutics BVAcute Myeloid Leukemia

Start: 2020-12-08End: 2023-04-30Target: 33Updated: 2022-06-21

Unknown Phase

Registry of Patients Having Received oNKord®

RecruitingNCT05290662

Glycostem Therapeutics BVAML

Start: 2022-06-14End: 2028-03-31Target: 50Updated: 2022-08-04

Related Papers

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Blood2025-11-03

Qualification of a flow cytometry-based method for the evaluation of <i>in vitro</i> cytotoxicity of GTA002 natural killer cell therapy.

2024-01-17

384 Single-cell transcriptomics, proteomics and in vitro cytotoxicity of allogeneic cryopreserved natural killer cell therapy GTA002 identify potent effector signatures

Regular and Young Investigator Award Abstracts2023-10-31

330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

Regular and Young Investigator Award Abstracts2023-10-31

245 Cord blood CD34<sup>+</sup> stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ natural killer cells which display selective cytotoxicity against B-cell leukemia

Regular and Young Investigator Award Abstracts2022-11-01

P1456: EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION

HemaSphere2022-06-012 citations

Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Blood2021-11-054 citations

A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, <i>ex vivo</i>-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.

Journal of Clinical Oncology2021-05-202 citations